OKYO Pharma Limited – LSE:OKYO.L

OKYO Pharma Limited stock price today

GBP 7.15
+5.75
+410.71%
Financial Health
0
1
2
3
4
5
6
7
8
9

OKYO Pharma Limited stock price monthly change

-11.95%
month

OKYO Pharma Limited stock price quarterly change

-74.07%
quarter

OKYO Pharma Limited stock price yearly change

-68.89%
year

OKYO Pharma Limited key metrics

Market Cap
 23.22M
Enterprise value
 N/A
P/E
 -1.8
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 -29.87
PEG ratio
 0.02
EPS
 N/A
Revenue
 N/A
EBITDA
 -2.51M
Income
 -2.48M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

OKYO Pharma Limited stock price history

OKYO Pharma Limited stock forecast

OKYO Pharma Limited financial statements

Profit Margin

OKYO Pharma Limited (LSE:OKYO.L): Profit margin
Jan 2019 0 -939.68K
Mar 2019 0 -939.68K
Jun 2020 0 -303.59K
Sep 2020 0 -303.59K
OKYO.L income statement history

Debt to Assets

OKYO Pharma Limited (LSE:OKYO.L): Debt to assets
Mar 2021 5138017 1.28M 24.99%
Sep 2021 4176976 494.83K 11.85%
Mar 2022 3273912 1.03M 31.47%
Sep 2022 1588953 1.89M 119.49%
OKYO.L balance sheet history

Cash Flow

OKYO Pharma Limited (LSE:OKYO.L): Cash Flow
Jan 2020 -266.37K -3.94K 194.78K
Mar 2020 -266.37K -3.94K 194.78K
Jun 2020 -266.37K -3.94K 194.78K
Sep 2020 -266.37K -3.94K 194.78K
OKYO.L cash flow history

OKYO Pharma Limited alternative data

OKYO Pharma Limited
Employees

OKYO Pharma Limited (LSE:OKYO.L): Employee count
Aug 2023 7
Sep 2023 7
Oct 2023 7
Nov 2023 7
Dec 2023 7
Jan 2024 7
Feb 2024 7
Mar 2024 7
Apr 2024 7
May 2024 7
Jun 2024 7
Jul 2024 7

OKYO Pharma Limited other data

OKYO Pharma Limited
Executives

Insider Compensation
Dr. Gary S. Jacob Ph.D. (1947) Chief Executive Officer & Director
 $290,840

Frequently Asked Questions (FAQ)

  • What's the price of OKYO Pharma Limited stock today?

    One share of OKYO Pharma Limited stock can currently be purchased for approximately $7.15.

  • When is OKYO Pharma Limited's next earnings date?

    Unfortunately, OKYO Pharma Limited's (OKYO.L) next earnings date is currently unknown.

  • Does OKYO Pharma Limited pay dividends?

    No, OKYO Pharma Limited does not pay dividends.

  • How much money does OKYO Pharma Limited make?

    OKYO Pharma Limited has a market capitalization of 23.22M.

  • What is OKYO Pharma Limited's stock symbol?

    OKYO Pharma Limited is traded on the LSE under the ticker symbol "OKYO.L".

  • What is OKYO Pharma Limited's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of OKYO Pharma Limited?

    Shares of OKYO Pharma Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are OKYO Pharma Limited's key executives?

    OKYO Pharma Limited's management team includes the following people:

    • Dr. Gary S. Jacob Ph.D. Chief Executive Officer & Director(age: 78, pay: $290,840)

  • How many employees does OKYO Pharma Limited have?

    As Jul 2024, OKYO Pharma Limited employs 7 workers.

  • When OKYO Pharma Limited went public?

    OKYO Pharma Limited is publicly traded company for more then 7 years since IPO on 17 Jul 2018.

  • What is OKYO Pharma Limited's official website?

    The official website for OKYO Pharma Limited is okyopharma.com.

  • How can i contact OKYO Pharma Limited?

    OKYO Pharma Limited can be reached via phone at +44 20 7495 2379.

OKYO Pharma Limited company profile:

OKYO Pharma Limited

okyopharma.com
Exchange:

LSE

Full time employees:

7

Industry:

Biotechnology

Sector:

Healthcare

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

+44 20 7495 2379
55 Park Lane
London, W1K 1NA

:
ISIN: GG00BD3FV870
CUSIP: G6724L108